



AMENDMENT TRANSMITTAL LETTER (Small Entity)				Docket No. ISPH-0623	
Applicant(s): Karras and Condon					
Serial No. 10/033,742	Filing Date December 28, 2001	Examiner T. Gibbs	Group Art Unit 1635		
Invention: ANTISENSE MODULATION OF MACROPHAGE INFLAMMATORY PROTEIN 3α ALPHA EXPRESSION					
TO THE ASSISTANT COMMISSIONER FOR PATENTS:				RECEIVED MAR 26 2003 TECH CENTER 1600/2900	
Transmitted herewith is an amendment in the above-identified application. <input checked="" type="checkbox"/> Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted. <input type="checkbox"/> A verified statement to establish Small Entity status under 37 FR 1.27 is enclosed. The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	12 -	20 =	0 x	\$9.00	\$0.00
INDEP. CLAIMS	1 -	3 =	0 x	\$42.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ A duplicate copy of this sheet is enclosed. <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1619 A duplicate copy of this sheet is enclosed. <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.					
Signature  Jane Massey Licata Reg. No. 32,257 Licata & Tyrrell P.C. 66 E. Main Street Marlton, NJ 08053 Tel: 856-810-1515 Fax: 856-810-1454			Dated: March 20, 2003		
CC:			I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.		
			Signature of Person Mailing Correspondence		
			Typed or Printed Name of Person Mailing Correspondence		



ISPH-0623

CERTIFICATE OF EXPRESS MAILING

Express Mail" Label No. **EV357419932US**

Date of Deposit **March 20, 2003**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the "BOX SEQUENCE", U.S. Patent & Trademark Office, P.O. Box 2327, Arlington, VA 22202.

- 1) Amendment Transmittal Letter (2 copies);
- 2) Reply under 37 C.F.R. § 1.111;
- 3) Return Post Card;
- 4) Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825;
- 5) Sequence listing; and
- 6) Diskette containing computer readable copy of Sequence Listing.



JANE MASSEY LICATA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ISPH-0623

Inventors: Karras and Condon

Serial No.: 10/033,742

Filing Date: December 28, 2001

Examiner: T. Gibbs

Group Art Unit: 1635

Title: Antisense Modulation of Macrophage
Inflammatory Protein 3-Alpha Expression

"Express Mail" Label No. EV357419932US
Date of Deposit March 20, 2003

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
U.S. Patent & Trademark Office, Box Sequence,
P.O. Box 2327, Arlington, VA 22202.

By Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

U.S. Patent & Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825

- (XX) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.

- () I hereby state that the amendments, made in accordance with **37 CFR §1.825(a)**, included in the substitute sheet(s) of the Sequence Listing were made to conform to the current Sequence Listing Rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, contains identical data to that originally filed.

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: March 20, 2003

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515